
Sign up to save your podcasts
Or


Back in April 2020, AstraZeneca was hailed as a frontrunner in the race to get an effective vaccine to market. A year later, after a series of trial pauses, communication blunders, and PR problems, the vaccine is on the cusp of FDA approval.
By all accounts, the company succeeded in making a safe, effective vaccine. So why has there been so much confusion about its rollout?
Guest:
Peter Aldhous, science reporter at Buzzfeed News
Host
Lizzie O’Leary
Learn more about your ad choices. Visit megaphone.fm/adchoices
By Slate Podcasts3.9
10531,053 ratings
Back in April 2020, AstraZeneca was hailed as a frontrunner in the race to get an effective vaccine to market. A year later, after a series of trial pauses, communication blunders, and PR problems, the vaccine is on the cusp of FDA approval.
By all accounts, the company succeeded in making a safe, effective vaccine. So why has there been so much confusion about its rollout?
Guest:
Peter Aldhous, science reporter at Buzzfeed News
Host
Lizzie O’Leary
Learn more about your ad choices. Visit megaphone.fm/adchoices

38,168 Listeners

6,763 Listeners

9,216 Listeners

8,480 Listeners

4,022 Listeners

3,524 Listeners

1,023 Listeners

5,626 Listeners

1,862 Listeners

112,220 Listeners

2,364 Listeners

2,069 Listeners

23,923 Listeners

2,138 Listeners

7,228 Listeners

2,407 Listeners

5,824 Listeners

444 Listeners

16,196 Listeners

739 Listeners

1,677 Listeners